KTMC Icon
Investors in Lantheus Holdings, Inc. are facing a potential class action lawsuit alleging securities fraud. The law firm of Kessler Topaz Meltzer & Check, LLP announced on October 5, 2025, that it has filed the lawsuit on behalf of shareholders who acquired Lantheus securities during the period from February 26, 2025 to August 5, 2025. The firm is urging affected investors to take action before the lead plaintiff deadline of November 10, 2025.
The complaint claims that Lantheus misled investors regarding the competitive position of its product, PYLARIFY. Specifically, it alleges that the company failed to accurately assess pricing dynamics, which may have jeopardized the product’s market standing. The lawsuit further alleges that Lantheus’ decision to increase prices in early 2025, despite previous price erosion, opened the door for increased competition that could impact revenues and growth prospects.
According to the notice issued by Kessler Topaz Meltzer & Check, the firm is prepared to represent investors who believe they have suffered significant losses as a result of the alleged misconduct. Investors can choose to be appointed as lead plaintiffs, which involves acting on behalf of all class members in guiding the litigation process. The lead plaintiff typically represents those with the largest financial interest in the case.
For those not wishing to take an active role, remaining an absent class member does not affect the ability to participate in any recovery that may arise from the lawsuit. Kessler Topaz Meltzer & Check encourages all investors affected by the situation to reach out for further information.
The firm has established a reputation for excellence in prosecuting class action lawsuits, recovering billions for victims of corporate misconduct. Investors interested in learning more about their rights or the lawsuit against Lantheus can visit the firm’s website or contact attorney Jonathan Naji, Esq. directly at (484) 270-1453.
Lantheus Holdings, based in Radnor, Pennsylvania, is publicly traded on the NASDAQ under the ticker symbol LNTH. The lawsuit reflects ongoing scrutiny of corporate practices in the healthcare sector, particularly regarding transparency and accountability to investors. As the case develops, it may have significant implications for Lantheus and its shareholders.
For more information or to sign up for the case, visit the Kessler Topaz Meltzer & Check website or follow the provided link.
